Luye Pharma's Rykindo® NDA Filing Accepted by the U.S. FDA

SHANGHAI, May 30, 2019 /PRNewswire/ -- Rykindo® (LY03004), Luye Pharma's innovative, independently developed Extended-Release Microspheres formulation for injection, is one step closer to going on the U.S. market. The US Food and Drug Administration (FDA) has completed the filing review...

from PR Newswire: https://prn.to/2ETBwnB